Blog

These articles are for informational purposes, and are not intended to constitute legal advice. These articles are only the opinion of the authors and are not attributable to Muncy, Geissler, Olds & Lowe, P.C., or the firm’s clients.

GOLDEN BRIDGE TECHNOLOGY v. APPLE INC. (Fed. Cir. 2014) (P) – Submission of applicant’s own or acquiesced remarks in an IDS may constitute disclaimer

In general, although the “mere disclosure of potentially material prior art to the [PTO] does not automatically limit the claimed invention,” “an applicant’s remarks submitted with an [IDS] can be the basis for limiting claim scope.” In particular, as here,...

DIGITECH IMAGE TECHNOLOGIES v. ELECTRONICS FOR IMAGING, INC. (Fed. Cir. 2014) (P) – Manipulating existing information to generate additional information is not by itself patentable

“Without additional limitations, a process that employs mathematical algorithms to manipulate existing information to generate additional information is not patent eligible.” Tying the manipulation to an underlying data structure—even one that is technological in...

X2Y ATTENUATORS, LLC v. ITC (Fed. Cir. 2014) (P) – Labeling certain features as “essential” or “universal” to all embodiments constitutes disavowal

A statement directly or indirectly incorporated into the specification that the presence of a particular feature is “universal to all the embodiments” or is “an essential element among all embodiments or connotations of the invention” constitutes a clear and...

ABBVIE DEUTSCHLAND GMBH & CO. v. JANSSEN BIOTECH, INC. (Fed. Cir. 2014) (P) – Representative species must be diverse when relied upon to satisfy written description of broader genus

Absent any structural features common to the members of a claimed genus, the specification must disclose representative species that are diverse across the breadth of the claimed genus in order to satisfy the written description requirement. “[A]nalogizing the genus...

HILL-ROM SERVICES, INC. v. STRYKER CORPORATION (Fed. Cir. 2014) (P) – Prosecution statements in unrelated applications cannot be used to interpret claims

This case reaffirms Pfizer v. Ranbaxy that “statements made during prosecution of [a] later, unrelated [] patent cannot be used to interpret claims of [another] patent.” Further, because prosecution focuses on “what [a reference] discloses” whereas claim construction...

Topics